squamous cell carcinoma

[Lyell Immunopharma, Inc. (Globenewswire, Inc.)] Lyell Immunopharma, Inc. announced that US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.

[Reproductive Sciences] Researchers assessed the correlation between immune infiltration status, chemotherapeutics sensitivity, immune checkpoint proteins, and the signature.

[Lyell Immunopharma, Inc.] Lyell Immunopharma, Inc. announced that the US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.

[Therapeutic Advances in Medical Oncology] A multi-disciplinary advisory group of Italian cutaneous squamous cell carcinoma (CSCC) experts was convened to develop criteria to assist in identifying appropriate candidates for cemiplimab therapy in advanced CSCC, based on the literature and clinical experience.

[Rubius Therapeutics, Inc.] Rubius Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelia carcinoma and triple-negative breast cancer.

[Dermatology and Therapy] Investigators summarize the current cSCC literature with a focus on how differing clinical assessments within each of the five selected risk factors (perineural invasion, differentiation, depth of invasion, size, and location) can influence the evaluation of patient outcomes.